150
Participants
Start Date
November 17, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
TQB2102 for injection
TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Science, Beijing
NOT_YET_RECRUITING
Liaoning Cancer Hospital & Institute, Shenyang
NOT_YET_RECRUITING
The First Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
Jilin Cancer Hospital, Changchun
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Anhui Pronvincial Cancer Hospital, Hefei
NOT_YET_RECRUITING
Lu'an People's Hospital, Lu'an
NOT_YET_RECRUITING
Cancer Hospital Affiliated to Shandong First Medical University, Jinan
NOT_YET_RECRUITING
Linyi Cancer Hospital, Linyi
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
Ganzhou People's Hospital, Ganzhou
NOT_YET_RECRUITING
Chongqing University Cancer Hospital, Chongqing
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Sun Yat-Sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Jiangmen Central Hospital, Jiangmen
NOT_YET_RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
NOT_YET_RECRUITING
Suining Central Hospital, Suining
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine, Xi'an
NOT_YET_RECRUITING
Shanxi Cancer Hospital, Taiyuan
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY